TrialNature medicine2021
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial.
Binghe Xu et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
118 papers cite itlatest 60 shown
this paperpooled ittrialcites it